×

TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 4.35% SHAREHOLDING IN ABLYNX

REGULATED INFORMATION

GHENT, Belgium, May 22, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Taube Hodson Stonex Partners LLP.

Taube Hodson Stonex Partners LLP notified that they have exceeded the 3% threshold and now hold 2,363,541 Ablynx shares, which represent 4.35% of the current 54,324,572 outstanding shares of Ablynx.

Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Jonathan Birt, Chris Welsh, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com

pdf format of the press release http://hugin.info/137912/R/1923233/689689.pdf

HUG#1923233

Source: Ablynx